Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · IEX Real-Time Price · USD
46.16
+0.50 (1.10%)
May 17, 2024, 4:00 PM EDT - Market closed

Soleno Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2012
Selling, General & Admin
13.489.8410.818.766.93
Upgrade
Research & Development
25.1915.2721.4523.1916.27
Upgrade
Operating Expenses
38.6725.1132.2631.9523.2
Upgrade
Operating Income
-38.67-25.11-32.26-31.95-23.2
Upgrade
Other Expense / Income
0.32-1.04-1.35-7.317.58
Upgrade
Pretax Income
-38.99-24.07-30.91-24.64-30.77
Upgrade
Net Income
-38.99-24.07-30.91-24.64-30.77
Upgrade
Shares Outstanding (Basic)
168542
Upgrade
Shares Outstanding (Diluted)
168542
Upgrade
Shares Change
96.40%57.90%27.39%83.41%62.77%
Upgrade
EPS (Basic)
-2.36-2.87-5.81-5.85-13.50
Upgrade
EPS (Diluted)
-2.36-2.87-5.81-5.85-13.50
Upgrade
Free Cash Flow
-24.94-20.79-27.79-25.23-17.4
Upgrade
Free Cash Flow Per Share
-1.51-2.48-5.23-6.04-7.64
Upgrade
EBITDA
-36.71-21.81-28.66-22.4-28.43
Upgrade
Depreciation & Amortization
2.282.252.252.242.34
Upgrade
EBIT
-38.99-24.07-30.91-24.64-30.77
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).